Real world use of ixekizumab is associated with reductions in concomitant medications among biologic-experienced or biologic-naive patients with psoriasis

被引：0
|
作者：
Wu, Jashin J. [1 ]
Zhu, Baojin [2 ]
Burge, Russel [2 ]
Goldblum, Orin [2 ]
Choong, Casey [2 ]
Edson-Heredia, Emily [2 ]
Amato, David [2 ]
机构：
[1] Dermatol Res & Educ Fdn, Irvine, CA USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
9884
引用
收藏
页码：AB114 / AB114
页数：1
相关论文
共 50 条
  • [31] SWITCH PATTERNS AND TOTAL COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIASIS
    Wu, J.
    Pelletier, C.
    Ung, B.
    Tian, M.
    Ni, Q.
    Curtis, J. R.
    VALUE IN HEALTH, 2018, 21 : S426 - S426
  • [32] THE PSORIASIS STUDY OF HEALTH OUTCOMES (PSOHO) IN BIOLOGIC-NAIVE AND -EXPERIENCED PATIENTS: RESULTS FROM THE FIRST 217 PATIENTS
    Costanzo, A.
    Pinter, A.
    Lynde, C.
    Tsai, T. F.
    Schuster, C.
    Brnabic, A.
    Reed, C.
    Hill, J.
    Riedl, E.
    Radtke, M. A.
    VALUE IN HEALTH, 2020, 23 : S410 - S410
  • [33] Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
    Andrew Blauvelt
    Nianwen Shi
    Najwa Somani
    Russel Burge
    Baojin Zhu
    Terri Ridenour
    Scott Kern
    Carolyn Lew
    Nicole Zimmerman
    Mwangi Murage
    Clinical Drug Investigation, 2023, 43 : 185 - 196
  • [34] Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
    Blauvelt, Andrew
    Shi, Nianwen
    Somani, Najwa
    Burge, Russel
    Zhu, Baojin
    Ridenour, Terri
    Kern, Scott
    Lew, Carolyn
    Zimmerman, Nicole
    Murage, Mwangi
    CLINICAL DRUG INVESTIGATION, 2023, 43 (03) : 185 - 196
  • [35] Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting
    Strober, Bruce
    Patil, Dhaval
    McLean, Robert R.
    Moore-Clingenpeel, Melissa
    Guo, Ning
    Levi, Eugenia
    Lebwohl, Mark
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (08) : 3178 - 3187
  • [36] REAL-WORLD COSTS IN BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Pelletier, C.
    Udeze, C.
    Tian, M.
    VALUE IN HEALTH, 2019, 22 : S888 - S888
  • [37] Effectiveness and Safety of Apremilast in Biologic-Naive versus Biologic-Experienced Patients with Psoriatic Arthritis in Real-World Clinical Practice Settings in Germany: Interim Analysis of an Ongoing, Multicenter, Prospective, Non-interventional Study
    Wollenhaupt, Jurgen
    Bach, Christian
    Roemmler-Zehrer, Josefine
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [38] Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients
    van Lumig, P. P. M.
    van de Kerkhof, P. C. M.
    Boezeman, J. B. M.
    Driessen, R. J. B.
    de Jong, E. M. G. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (05) : 593 - 600
  • [39] Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients
    Dominguez-Sosa, Maria Sandra
    Cabrera-Ramirez, Maria Soledad
    Marrero-Ramos, Miriam del Carmen
    Davila-Quintana, Delia
    Cabrera-Lopez, Carlos
    Cuervo, Heleia Gonzalez
    del Rosario, Jesus Javier Benitez
    Carrillo-Diaz, Teresa
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [40] Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
    Strober, Bruce
    Patil, Dhaval
    McLean, Robert R.
    Moore-Clingenpeel, Melissa
    Guo, Ning
    Levi, Eugenia
    Lebwohl, Mark
    DERMATOLOGY AND THERAPY, 2022, 12 (06) : 1351 - 1365
12345